RT Journal Article
SR Electronic
A1 Hoyle, Brian
T1 Switching from RTV to COBI is Feasible in Patients with HIV-1 Who Have Mild-to-Moderate Renal Impairment
JF MD Conference Express
YR 2014
FD SAGE Publications
VO 14
IS 28
SP 10
OP 11
DO 10.1177/155989771428005
UL http://mdc.sagepub.com/content/14/28/10.abstract
AB Cobicistat (COBI; approved as Tybost™ in the European Union and under review in the United States) is well tolerated in HIV-1 patients with mild-to-moderate renal impairment. The latest results build on prior phase 3 data demonstrating the long-term (144-week) noninferiority of COBI—which is eliminated mainly by liver metabolism, negating the need for dose adjustment in renal-impaired patients—to ritonavir as a protease inhibitor booster in treatment of HIV-1 infection in treatment-naïve patients.